News
ZOM
0.1293
-0.77%
-0.0010
Weekly Report: what happened at ZOM last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ZOM last week (0401-0405)?
Weekly Report · 04/08 09:47
ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023
Zomedica just reported results for the fourth quarter of 2023. The company reported revenue of $7.34 million. Zomedica reported earnings per share of -2.3 cents. This was 4.81% better than the analyst estimate for the quarter.
Investorplace · 04/02 00:53
Zomedica Achieves Record Revenue and Strong Growth
TipRanks · 04/01 21:37
Zomedica Q4 2023 GAAP EPS $(0.02), Sales $7.337M Beat $7.000M Estimate
Benzinga · 04/01 20:28
Zomedica reports Q4 results
Seeking Alpha · 04/01 20:15
Weekly Report: what happened at ZOM last week (0325-0329)?
Weekly Report · 04/01 09:47
Earnings Scheduled For April 1, 2024
Mach Natural Resources is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. Sharps Technology is expected to report earnings for its fourth quarter. Companies Reporting Before The Bell and After The Bell are expected to be in the spotlight.
Benzinga · 04/01 09:13
Notable earnings after Monday's close
Major earnings expected after the bell on Monday include: Zomedica Corp. And Canoo. Other major earnings slated for release after Monday's close include: Omeros Corporation and YTEN. For the full earnings season calendar, visit Seeking Alpha's earnings calendar.
Seeking Alpha · 03/31 21:35
Weekly Report: what happened at ZOM last week (0318-0322)?
Weekly Report · 03/25 09:49
Weekly Report: what happened at ZOM last week (0311-0315)?
Weekly Report · 03/18 09:48
Zomedica Strives to Maintain NYSE Listing
Zomedica Corp. Is engaged with NYSE American to address compliance issues after failing to meet listing standards. The company's stock will remain listed despite shareholders rejecting a proposed 80:1 reverse stock split. Zomedica specializes in veterinary health products for animals and is listed on the NYSE.
TipRanks · 03/15 13:37
Zomedica says talks ongoing with NYSE American to regain listing compliance
Zomedica says talks ongoing with NYSE American to regain listing compliance. The company says its shares will remain listed on the NYSEAmerican at this time. Zomedica Corp. Says talks are ongoing with New York Stock Exchange to regain compliance with its listing standards.
Seeking Alpha · 03/13 21:12
Zomedica Says Continuing Dialogue With Senior Regulatory Staff At NYSE American Regarding Next Steps To Regaining Compliance With Its Listing Standards
Zomedica shares will remain listed on the NYSE American at this time. A Special Meeting of Shareholders was held on February 28, 2024. The company was unable to effect an 80:1 share consolidation corporate action. Zomedica received formal notice that it was not in compliance with continued listing standards.
Benzinga · 03/13 20:57
Weekly Report: what happened at ZOM last week (0304-0308)?
Weekly Report · 03/11 09:46
Weekly Report: what happened at ZOM last week (0226-0301)?
Weekly Report · 03/04 09:48
Weekly Report: what happened at ZOM last week (0219-0223)?
Weekly Report · 02/26 09:52
Weekly Report: what happened at ZOM last week (0212-0216)?
Weekly Report · 02/19 09:53
Weekly Report: what happened at ZOM last week (0205-0209)?
Weekly Report · 02/12 09:48
Weekly Report: what happened at ZOM last week (0129-0202)?
Weekly Report · 02/05 09:52
More
Webull provides a variety of real-time ZOM stock news. You can receive the latest news about Zomedica Corp through multiple platforms. This information may help you make smarter investment decisions.
About ZOM
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).